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 1 
Abstract 2 
Kawasaki disease (KD) is an acute, systemic vasculitis of childhood and confers a 25% risk of developing 3 
coronary artery aneurysms (CAA). Its aetiology is unknown, but the incidence is increasing rapidly with linked 4 
gene polymorphisms having been identified. A constellation of symptoms, epidemics and seasonality all 5 
implicate an unidentified infective or environmental cause. Intravenous immunoglobulin therapy (IVIG), aspirin 6 
and steroids all form the mainstay of acute treatment and reduces the incidence of CAA if given before 7 days. 7 
However, in some, these lesions persist and require ongoing management during follow up during childhood and 8 
into adult life. Evidence for further investigations in order to minimise complications is presented in order to 9 
minimise the myofibroblast proliferation and stenosis in the long term.  10 
 11 
Keywords 12 
Kawasaki disease, vasculitis, coronary artery, aneurysms. 13 
  14 
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 15 
Background 16 
Kawasaki disease (KD) is an acute, systemic vasculitis of medium-sized, primarily muscular arteries that typically 17 
affects children and is generally self-limiting in nature(1). The incidence of KD highest in children under five 18 
years, 85% of all diagnoses are made in this demographic, but can affect any age (2). It affects boys more than 19 
girls, at a ratio of approximately 1.6:1 (3). The major complication is the development of coronary artery 20 
aneurysms CAA; a potentially life-threatening condition. Consequently, there is a higher risk of myocardial 21 
infarction, aneurysm rupture, coronary artery thrombus formation and sudden cardiac death.  22 
 23 
The diagnostic criteria of complete KD are the presence of a fever lasting five days or more and at least four of 24 
the following five criteria: 25 
 26 
• bilateral, painless, non-exudative conjunctivitis 27 
• cervical lymphadenopathy; generally larger than 1.5 cm and commonly unilateral 28 
• polymorphous exanthema  29 
• changes in lip or oral mucosa: commonly present as red, cracked lips; ‘strawberry tongue’ which is 30 
seen as glossitis with hyperplastic fungiform papillae or generalised diffuse erythema or the oropharynx 31 
• changes of the extremities, particularly erythema and oedema of the palms and soles of the feet; this 32 
can progress later to desquamation of the skin 33 
 34 
Incomplete KD may be seen with only 3 of the criteria in addition to fever; detection of coronary artery dilatation 35 
or aneurysm on echocardiography requires only a fever and two of the criteria are to make a diagnosis of 36 
atypical Kawasaki disease.  37 
 38 
In developed countries, Kawasaki disease has overtaken rheumatic fever as the leading cause of acquired heart 39 
disease in children (4). Rates of Kawasaki disease have steadily increased (5). In addition, while there is a 40 
prevalence of Kawasaki disease in every country, Japan has the highest incidence of this condition and it is still 41 
rising (6, 7). 42 
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 43 
The signs and symptoms of this condition develop over approximately 10 days and, in most cases, seemingly 44 
resolve spontaneously. However, this condition causes coronary artery aneurysms in up to 25% of children if left 45 
untreated: this is a statistic taken from the era of pre-intravenous immunoglobulin therapy, which is the mainstay 46 
treatment of Kawasaki disease today (8). Current data has shown a regression of coronary artery aneurysms in 47 
up to 75% of cases treated with IVIG(9), with approximately 3–6% of patients developing coronary artery 48 
aneurysms despite treatment (10, 11). 1% of patients develop giant coronary artery aneurysms, which carry the 49 
worst clinical prognosis.  50 
 51 
There is also a subset of KD patients who fail to respond to IVIG; arguably demonstrating a more aggressive 52 
disease progression. The Kobayashi score uses laboratory findings and is routinely used in Japan to predict 53 
those with IVIG resistance, thus ensuring that second-line treatment is delivered promptly. However, this score 54 
did not predict response reliably in the US or the UK. Genetic variations between populations may lead to 55 
different laboratory results and therefore calculations may be unable to accurately predict IVIG resistance.  56 
 57 
As a mechanism for the disease process remains unknown, no laboratory finding is pathognomonic for Kawasaki 58 
disease. Identification of KD is therefore dependent on clinical acumen alone. The constellation of symptoms is 59 
non-specific and is seen in other viral illnesses, which could delay prompt recognition and administration of 60 
treatment. Effective steps towards prevention are not feasible either and treatment options for the cardiac 61 
complications include invasive procedures such as angioplasties, stent placement and coronary-bypass 62 
surgeries (12). These reasons outline why Kawasaki disease is a paediatric research priority.  63 
 64 
 65 
Aetiology 66 
 67 
The aetiology of Kawasaki disease is poorly understood and several different theories have been proposed. 68 
Current evidence suggests the interaction of an unknown infective cause(s) (13) and a genetic predisposition are 69 
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needed to develop KD. To what degree these factors influence KD, and if one is stronger than the other, has not 70 
been formally elucidated.  71 
 72 
It is, however, possible to argue that genetic factors have an important role in KD(14).  Such genome wide 73 
association studies have suggested that the polymorphism of the IgG receptor may have a part to play in the 74 
susceptibility of children to KD and to the coronary artery aneurysms(15). The rates of Kawasaki disease are 75 
significantly higher in East Asian populations: particularly Japan, which has the highest incidence of Kawasaki 76 
disease in the world, at 264 per 100,000 children under 5 years (16). This is followed by Korea and Taiwan, 77 
where rates are 134 and 66 respectively; the higher rates in these East Asian countries suggests some genetic 78 
or environmental link. It could be argued that Kawasaki disease-associated pathogens (as yet undetermined) 79 
show a degree of endemicity, or that the lifestyle followed in these three countries exposes children to the 80 
pathogens, rather than any genetic bias conferring increased susceptibility. However, population studies in the 81 
US show otherwise. The Japanese-American population that resides in Hawaii, USA has an incidence of 210 per 82 
100,000, whereas the rate in Caucasian American children living in the same state is 13/100,000 (17). The 83 
incidence in the Japanese-American population is approximately sixteen times greater than the Caucasian 84 
population in the same environment, which could imply that the development of Kawasaki disease is dependent 85 
on genetic factors and pathogen exposure (18). 86 
 87 
Epidemiologically, the pattern of incidence suggests an infective cause. There have been three major nationwide 88 
epidemics of Kawasaki disease in Japan, all demonstrating origination in a specific area and countrywide spread 89 
over a 3-month period; similar to an epidemic (19). The acute, self-limiting nature of KD is another hallmark of 90 
viral disease. Since the identification of Kawasaki disease, a multitude of different pathogens have been 91 
investigated; these range from the bacterial (Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas 92 
aeruginosa), to viral (herpesvirus, adenovirus and the Epstein-Barr virus) (20). 10% of patients with complete 93 
Kawasaki disease have been shown to have low-level viral titres of human adenovirus present. The authors 94 
concluded that this presented some link between infection with human adenovirus and the onset of Kawasaki 95 
disease(21) but this has not yet been upheld as a definitive cause.  96 
    97 
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However, it is important to note that titres of human adenovirus can persist years after the onset of the initial 98 
infection (22), and that this this virus is particularly common in children: i.e. the 10% with detectable titres may 99 
have had the infection before, leading to the detectable viral load count. In addition, this study remarked that the 100 
sensitivity of their PCR quantification was high, but did not offer any way in which they could draw a discrepancy 101 
between viral load due to current infection or previous, and therefore unrelated, infection. Indeed, many papers 102 
have hypothesised different infective triggers; herpesvirus (20) is another example. The constellation of 103 
symptoms commonly seen in Kawasaki disease (fever, rash, irritability) are also seen in infection with 104 
adenoviruses and herpes viruses. Similar haematological abnormalities have also been observed, such as 105 
neutrophilia and high erythrocyte sedimentation rates (23). However, unlike the other two viruses mentioned, 106 
there is no evidence of human-to-human transmission in Kawasaki disease. Although this may appear to 107 
contradict with the earlier assertion of nationwide epidemics in Japan as these three events were comparable to 108 
viral outbreaks in their spread, epicentre, and seasonal timing, there was no evidence of human-to-human 109 
transmission found.  110 
 111 
Peaks in occurrence appear to be dictated by the seasons, similar to what is seen in the pattern of viral infection 112 
(24). However, these peaks have a different seasonality across the world: while Japan, mainland US, Canada 113 
and the UK have all shown peaks during the winter months (25, 26) (27), in Hawaii however there was no 114 
seasonality at all, whereas China had its lowest incidence during the winter, and highest in the spring.  115 
 116 
Peak incidence is in children between 18 and 24 months of age, with diagnoses of Kawasaki disease being 117 
made in children less than 3 months old being uncommon. This suggests that a child may have some protection 118 
from developing this disease until a certain age, implicating a role for transplacental antibodies. These antibodies 119 
play a powerful role in fighting bacterial infections, as demonstrated by children with congenital 120 
agammaglobuliunaemia (28) who commonly only begin to present with bacterial infections at 6 to 9 months (29); 121 
the onset of these bacterial infections do not generally coincide with the cessation of breast-feeding, implying 122 
that it is the antibodies transferred across the placental barrier that are responsible for this protective effect and 123 
not those found in the mother’s breast milk. In addition, the effects of immunity conferred in utero tend to diminish 124 
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within the first 3 months of life; further suggesting the role of transplacental antibodies. This pattern further 125 
suggests an infective cause being a trigger in developing Kawasaki disease. 126 
 127 
By contrast, the rarity of Kawasaki disease after 5 years of age (30) implies that a matured immune system may 128 
be more adept at mounting an appropriate immune response: again, suggesting an infective cause. In addition, 129 
the greater incidence in boys supports this hypothesis as many infectious disease present more commonly in 130 
males than females (31). Furthermore, recurrence rates are low (at 3-4%), once again implying that the body is 131 
able to mount an immune response which prevents future cases (3). 132 
 133 
Genetics  134 
 135 
There is a greater risk of developing Kawasaki disease if there is an affected sibling or parent, implying a genetic 136 
role in the development of this disease (32). However, it is also important to note potential limitations of such 137 
data. (32). In this study, the number of patients affected with Kawasaki disease increased. The number of 138 
parents that had been diagnosed with KD in their childhood also increased. This trend displayed evidence of a 139 
genetic link between developing this condition. However, it is important to note that this study was carried out 140 
over a period of ten years from 1999 to 2008 and the increased proportion of affected patients reported every 141 
year may be due to an increased awareness of the condition amongst medical professionals, and therefore a 142 
greater rate of diagnosis, rather than an actual greater rate of prevalence.  143 
 144 
In an attempt to understand the pathophysiology of Kawasaki disease, large genome studies have been 145 
conducted in populations where prevalence is high. Certain common single nucleotide polymorphisms have been 146 
observed in specific genes in individuals affected by KD. It is possible that these confer some level of genetic 147 
susceptibility in developing this condition. A functional polymorphism was identified that exceeded the formal 148 
threshold for genome-wide significance in the IgG receptor gene (FCGR2A) (15). Functional polymorphisms of 149 
this IgG receptor gene influence the phenotype of the individual by stratifying their responses to IgG as ‘strong’ 150 
or ‘weak.’ The particular single nucleotide polymorphism (SNP) that was identified had been shown to confer an 151 
increased risk of developing ulcerative colitis (33) in a Japanese population. This same SNP was shown to 152 
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confer a decreased risk in developing systemic lupus erythematosus (34) in a European population. The 153 
involvement of this SNP in two autoimmune conditions suggests a dysfunctional immune response being 154 
fundamental in the development of Kawasaki disease in individuals. The role of an IgG-mediated immune 155 
response in the pathogenesis is also supported by IVIG being a mainstay of treatment, which will be discussed 156 
later in further detail.   157 
 158 
Genomic studies showed three SNPs in a sodium-calcium transporter gene being validated for a significantly 159 
associated pathway (35). In KD patients, the carriers of homozygous ‘risk’ alleles of the SLC8A1 gene have been 160 
shown to be at a greater risk of developing coronary artery aneurysms; the protein (NCX1) encoded was 161 
expressed in the inflammatory cells of the aneurysm wall. Altered calcium signalling appears to increase the risk 162 
of cardiac complications, implying a more aggressive course of disease. In addition, polymorphisms of IPTKC, a 163 
negative regulator of T-cell activations, have been associated with KD patients, and especially in those with 164 
coronary artery lesions (36).  This is a Ca2+/NFAT signalling pathway. Impaired calcium signalling suggests a 165 
more severe disease progression, as the functional polymorphism of IPTKC was strongly associated with 166 
patients who developed cardiac sequelae.  167 
 168 
Calcineurin inhibitors have been shown to treat KD in IVIG-resistant patients (37): this suggests that impaired 169 
calcium signalling confers an increased risk of developing complications and its role should be further 170 
researched. 171 
 172 
Up to 20% of KD patients fail to defervesce within 36 hours of IVIG therapy. It implies a more aggressive course 173 
of disease and longer period spent in acute inflammation, resulting in a greater likelihood of developing coronary 174 
artery aneurysm. The identification of these patients earlier could therefore improve clinical outcome, and so the 175 
Kobayashi score (38) was developed to predict patient response. It uses 7 laboratory and clinical findings to 176 
predict the unresponsiveness in KD patients to IVIG therapy. It has been used with positive results in the 177 
Japanese population; however, when used in the US and UK (39, 40), it failed to reliably predict IVIG 178 
responsiveness. Despite removal of patients with incomplete Kawasaki disease in the model, the Kobayashi 179 
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score still failed to reliably predict IVIG response in a UK population. This suggests that the pattern of disease 180 
may differ according to ethnicity.  181 
 182 
Pathophysiology 183 
 184 
Although a specific infectious trigger has not yet been noted, the pathophysiology of this condition has been 185 
closely studied. Vasculitis has been observed in the cardiovascular, gastrointestinal, respiratory, integumentary, 186 
dermatological, urinary and nervous system(41); however, the most clinically significant is the vasculitis of 187 
coronary arteries, leading to coronary artery aneurysms. This is because it has resulted in myocardial infarction, 188 
ischaemic heart disease and sudden cardiac death in patients (42).  189 
 190 
The progression of acute Kawasaki disease can be split into separate stages according to the number of days 191 
from the initial onset. Stage I (0-9 days after onset) is characterised by inflammation of the adventitia (also known 192 
as perivasculitis); stage II (12-25 days) often shows vasculitis of medium-sized, muscular arteries; stage III (28-193 
31 days) is where pan-vasculitis is most prominent, and where arterial aneurysm development is commonly 194 
observed (3).  195 
 196 
Analysis of tissue, blood and arterial walls has provided insight into the mechanism of disease progression. 197 
Tissue infiltration of lymphocytes, macrophages, plasma cells and large mononuclear cells demonstrates that 198 
there is an acute inflammatory response (43) and despite elevated levels of neutrophils in the blood (44) the lack 199 
of neutrophil invasion shows that these cells are not the chief mediator. While physiological levels of CD4 200 
lymphocytes outnumber CD8, there was a 4–5 fold increase reported in CD8 lymphocytes in the arterial wall as 201 
compared to CD4. This is consistent with findings that are seen in the presence of an intracellular pathogen (45), 202 
thus providing evidence for a ubiquitous agent involved in the pathogenesis of Kawasaki disease. There was no 203 
significant change reported in the number of circulating CD8 lymphocytes in the acute stage, which indicates that 204 
the disease process actively recruits these lymphocytes into the arteries.  205 
 206 
Page 8 of 19
https://mc04.manuscriptcentral.com/fm-fca
Future Cardiology
For Review Only
Kawasaki Disease- coronary artery aneurysms 
An elevated IgA plasma cell proliferation (46) – greater than IgG and IgM – is seen in the arterial wall: this is 207 
unusual as IgA domination is seen in mucosal or lymphoid structures rather than vascular structures. This 208 
appears to suggest a stimulation of the immune system, likely at a mucosal site, which led to a systemic 209 
conversion of B lymphocytes to IgA secreting plasma cells.  210 
 211 
A marked rise of IgA plasma cells appeared in the upper respiratory tract, pancreas, coronary arteries and 212 
kidneys of patients who had died of acute Kawasaki disease (47). This same study showed increased IgA 213 
plasma cell infiltration was also seen in children who had died of an acute respiratory tract infection; the similarity 214 
of these findings suggests the involvement of an infectious agent in Kawasaki disease. Studies have shown that 215 
the method by which IgA expansion is controlled is oligoclonal (46, 48), which suggests an infective cause. All 216 
synthetic antibodies that bound to acute KD tissues (48) detected antigen in all cytoplasmic inclusion bodies in 217 
acute KD affected ciliated bronchial epithelium. Inclusion bodies are pivotal in the pathophysiology and this 218 
finding is consistent with KD being caused by a microbial pathogen.  219 
 220 
However, it is important to note that all of these studies used samples collected from deceased patients whose 221 
death was attributed to Kawasaki disease complications. Whilst all these data show similar results, which 222 
increases confidence in the conclusions obtained, it is unclear to what extent these conclusions can be 223 
extrapolated to patients that are a) alive, but with coronary artery lesions, b) alive, and with no coronary artery 224 
lesions and c) alive, with regressed coronary artery lesions. Due to the relatively recent history of Kawasaki 225 
disease, there has been little research into the coronary artery status of those who have died of a non-Kawasaki 226 
disease related cause, and therefore this still remains unknown. It will be interesting to study those particular 227 
patients; however, cataloguing and recruiting these patients will pose logistical challenges.  228 
 229 
Treatment  230 
 231 
Current guidelines outlining treatment of acute KD include intravenous immunoglobulin therapy and high-dose 232 
aspirin. Although aetiology and a definitive summary of the pathophysiology remain to be elucidated, numerous 233 
prospective, controlled trials have shown the efficacy of this regime (11, 49, 50).  234 
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 235 
Intravenous immunoglobulin therapy in the treatment of KD has reduced rates of coronary artery aneurysm 236 
formation from 25% to 3-6% in affected patients; however, around 20% of patients show IVIG-resistance, which 237 
is qualified as a fever persisting 36 hours after IVIG was administered or a recrudescent fever (51, 52). C-238 
reactive protein levels persisting at >3 mg/L after 36 hours can also be a marker of IVIG-resistant disease.  239 
 240 
2g/kg as a single dose is constituted as optimum therapy, and has shown greater efficacy than divided low-doses 241 
(400 mg/kg/day) administered over several days. Meta-analysis concluded that both caused defervescence, but 242 
the higher, single dose provided better protection against the formation of coronary artery lesions (49, 50). The 243 
improvement of symptoms with IVIG and the association between a functional polymorphism in an IgG receptor 244 
gene demonstrate that IgG has some role in the pathophysiology. In addition, even in IVIG-resistant patients, the 245 
rash, swelling and erythema also associated with KD often improve (53). Reduced cytokine levels, decreased 246 
number of circulating T cells, macrophages and neutrophils, and increased number of natural killer cells have all 247 
been noted after IVIG treatment; however, how these changes are induced have not been described (53).  248 
 249 
The use of aspirin remains slightly more controversial: the use of salicylates is strongly contraindicated in most 250 
paediatric cases due to the risk of Reye’s syndrome (54, 55) and KD is one of the few conditions in childhood 251 
which is treated with aspirin. Although the duration of the characteristic fever appeared to be reduced by high-252 
dose aspirin therapy (56), there was no change noted in response to IVIG, resolution of inflammation, or 253 
incidence of coronary artery lesion (57, 58). After the febrile period, aspirin therapy is reduced from 30-50 254 
mg/kg/day to a low dose of 5mg/kg/day for 6 weeks and reassessed, depending on the presence or absence of 255 
any coronary artery abnormalities.  256 
 257 
IVIG-resistant therapy encompasses a second dose of IVIG at 2 g/kg, corticosteroids or both administered. Early 258 
analyses showed a positive association between corticosteroid therapy and increased coronary artery 259 
abnormalities. However, this finding has now been contributed to confounding, as in these retrospective studies 260 
the sicker patients were more likely to be given corticosteroids, and therefore more likely to develop lesions (59). 261 
The main indications for using adjunct corticosteroid therapy are: 262 
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 263 
1. Patients who are IVIG resistant, with a persisting or recrudescent fever after 36 hours from IVIG 264 
treatment onset 265 
2. Patients with features of very severe disease. In Japan, the Kobayashi score is used; however it has 266 
proven to be less accurate in other countries. Therefore, persistently high markers of cell injury and 267 
inflammation, such as raised CRP levels, liver dysfunction and anaemia are used 268 
3. Patients with pre-existing coronary artery and/or peripheral aneurysms 269 
 270 
Serum tumour necrosis factor-α (TNF-α) is elevated in KD patients, and in particular those who develop coronary 271 
artery aneurysms. Thus, anti TNF-α therapies such as infliximab are being investigated as alternative therapies; 272 
especially in patients unresponsive to IVIG. A 3-year-old patient, unresponsive to IVIG and methylprednisolone, 273 
defervesced in response to one dose of anti TNF-α (60). A retrospective study compared defervescence and 274 
length of hospital stay in IVIG-resistant patients treated with a second dose of IVIG and those treated with one 275 
dose of infliximab (61). Infliximab resulted in faster fever resolution and a shorter hospital stay. A recent 276 
randomised controlled trial (62) showed the same two results, with a greater response to infliximab (90.9%) than 277 
second-dose IVIG (65.6%). The size and power of these studies is limited, but demonstrates anti TNF-α as a 278 
potential therapeutic option.  279 
 280 
Calcineurin inhibitors (such as cyclosporin A) have been used in the treatment of refractory KD (63, 64); 281 
however, they should be used with caution as they can be toxic to the endothelium (65). The decision to 282 
prescribe these medications must therefore be made on a case-by-case basis.  283 
 284 
Coronary Artery Aneurysms 285 
Current studies suggest that 20- 24% of children, even if treated, will suffer from coronary artery aneurysms(27). 286 
The definition of an aneurysm can now be recorded as an indexed (z score) size of the coronary artery, based on 287 
the body surface area of the child (66). Coronary artery dilation is defined as z score +2 to 2.5, small aneurysms 288 
are with z score ≥ 2.5 but less than 5, moderate size CAA is seen in those with z score ≥ 5 but less than 10 and 289 
those who have giant CAA have a z score ≥10. We now know that it takes several years for many of these to 290 
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resolve, with reducing likelihood of complete resolution correlating with increasing size and complexity of 291 
coronary artery involvement (67). Recent AHA guidance details the long term outcome based on a severity 292 
scoring system, which may be opinion for the USA, but which has little evidence base there and uncertain 293 
relevance to the European or Asian population (68). We know that those children with giant CAA are those most 294 
likely to suffer from Major Adverse Coronary Events in the longer term, necessitating antiplatelet and anti-295 
coagulant medication and multiple and regular repeat imaging. 296 
For those children with just coronary dilation, or with no involvement at all, at the current time there is no 297 
evidence from the western world that these children are at risk. There is evidence from a variety of studies that 298 
the coronary arteries in this group may be abnormal in the long term in terms of coronary flow reserve (69) and 299 
endothelial-dependent brachial artery reactivity (70) but there is dispute about the presence or absence of 300 
coronary artery dysfunction (71) (72). No child, as far as we are aware, has been seen in the UK population, 301 
without having had CAA, who has then grown up to demonstrate premature coronary artery disease. Hence the 302 
recommendation is that these children can stop their aspirin and can be discharged from follow-up. The recent 303 
AHA guidelines concur with this, but it is clear that until we have five decades of follow-up in the UK population, 304 
we cannot be certain about the long-term outcome in this group. Since this group is 76% of the current UK 305 
incident population of children with KD (27), it will be important to revisit this in future years when we have longer 306 
term follow up.  307 
 308 
There is some evidence that those children who had small or medium CAA, in whom these resolved, should be 309 
followed up in the longer term (68, 73, 74). Our group have shown that they have circulating endothelial cells 310 
(75). This is in line with the American Heart Association Guidelines (76) (68) that suggest that there may be 311 
ongoing risk in these patients and advise ongoing imaging and dynamic myocardial and coronary flow studies. 312 
Long term outcome after even moderate aneurysms suggests that there may be coronary artery stenosis, only 313 
recognised by thallium scanning and not by stress testing (77). Hence there is recommendation that these 314 
children can either stop or continue their aspirin and could have long-term follow-up. In the UK, there is no 315 
evidence, yet, that these children are at risk of coronary events 316 
 317 
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The evidence that those children with persistent CAA may develop complications is now overwhelming. The risk 318 
of Major Adverse Coronary Event (MACE) increases with size, complexity and location of CAA (9) (68). In those 319 
with persisting CAA >4mm, there is a high risk of coronary artery endothelial thickening which might lead to 320 
complications of ischaemia, especially on exercise (78). In those with giant CAA (>8mm) or z>10, long-term 321 
outcome is poor, with 40% having MACE with myocardial infarction often leading to death.  322 
 323 
Kawasaki disease in Adulthood 324 
 325 
There has been no formal collection of data regarding the number of adult patients with a previous history of 326 
Kawasaki disease in the US or the UK. Estimations are that approximately 24,000 young adults (>18 years) in 327 
the US (42), with 8,400 of these patients classified at an AHA Risk level II or higher. Estimates for the UK have 328 
not yet been published but it appears that about 4% of young adults presenting with myocardial infarction have 329 
coronary angiograms indicative of previous KD (79). It is accepted that those patients who presented with giant 330 
aneurysms should undergo regular and routine follow up through adulthood. However, it is unclear what level of 331 
follow up treatment should be given to those with regressed aneurysms and those who presented with no 332 
coronary artery abnormalities. Prompt treatment with IVIG means that the majority of patients (76%) do not have 333 
these coronary artery lesions in the acute stage of KD. 334 
 335 
Due to the growing rate of diagnosis, cardiologists will be dealing with adult patients who have long-term 336 
sequelae from this condition. Although coronary artery aneurysms are the main complication, other 337 
cardiovascular abnormalities should also be investigated: myocarditis and valvulitis (80) has also been observed 338 
in KD patients. Myocardial fibrosis and aortic and mitral regurgitation can follow and lead to death.  339 
 340 
Studies in Japan showed that the standard mortality ratio (SMR) for young males with previous KD and cardiac 341 
sequelae was significantly higher than females with KD and age-matched population (81). This is one of few 342 
studies conducted that has investigated mortality rates in people with KD with no cardiac sequelae, and may 343 
indicate that patients with KD and no sequelae do not need routine follow-up. It suggests that paediatricians can 344 
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stop seeing these patients during childhood, as this demographic does not have a significantly greater risk of 345 
mortality.  346 
 347 
Childhood diagnosis of KD has been cited as a risk factor for accelerated coronary artery disease in adulthood 348 
(82) irrespective of lipid profile, suggesting that these patients should be followed up by cardiologists routinely. 349 
The only patients included in the test group for this study were patients with a historical KD diagnosis and cardiac 350 
sequelae: whether a KD diagnosis alone is a risk factor for accelerated atherosclerosis cannot be concluded. KD 351 
being a risk factor can be cited as a reason to follow up all patients in later life. However, as only those with 352 
coronary artery lesions were included in this study, it is not entirely possible to state that KD with no cardiac 353 
sequelae is also a risk factor.  354 
 355 
Autopsy results of those with KD who died after the acute stage (all individuals were >15 years old at the time of 356 
death) showed different histological results in non-aneurysm coronary arteries(83). There was increased ‘new’ 357 
intimal thickening of the non-affected arteries, along with previous thickening during the arteritis phase in acute 358 
KD. Although these arteries were declared non-affected, there were still histological changes that remained 359 
during the patient’s life, and can therefore not be excluded as a risk factor for atherosclerosis. The coronary 360 
arteries of a KD patient with no coronary artery lesion were compared to KD patients with the cardiac sequelae, 361 
and both showed platelet-derived growth factor (A) and inducible nitrate synthase in intimal smooth muscle cells 362 
(84). This was not seen in patients with no KD. Inflammatory markers were still present in this patient at 13 363 
months post diagnosis, with an apparently normal coronary artery, and therefore KD with no coronary artery 364 
lesions can still pose as a risk factor for atherosclerosis. Although these are the histological findings of only one 365 
patient, and the results cannot be extrapolated to all, autopsy reports of children with no cardiac sequelae are 366 
incredibly rare. Obtaining tissue from patients to investigate this poses a challenge in itself, and in light of the 367 
data available, it is better practice to regularly follow up KD patients: even those with no history of coronary artery 368 
aneurysms.  369 
 370 
Future perspective 371 
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There are a variety of issues yet to be solved. First of all we need a certain marker for diagnosis and a known 372 
aetiology. Then we need to have better recognition and diagnosis with more effective acute treatment to reduce 373 
the incidence of coronary artery aneurysms. This would reduce long term complications and would be best 374 
accompanied by effective therapy at reducing myofibroblastic proliferation and hence the risk of major adverse 375 
coronary events.  376 
 377 
Executive summary 378 
In summary, therefore, we have described the presentation, treatment and long term management strategy for 379 
children and young adults with this increasingly common disease.  380 
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